Qfitlia (fitusiran), developed by French company Sanofi, is a subcutaneous treatment that helps prevent bleeding. The approval in the U.S. applies to patients aged 12 and older who have hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors.
The treatment is administered once every other month, while several other therapies are...
New drug to simplify treatment of hemophilia
A new type of treatment for hemophilia, which only needs to be administered every two months, has been approved by the U.S. Food and Drug Administration (FDA).
Photo: Colourbox
Vill du få åtkomst till allt?
Prova 30 dagar för 0 kr.
Inga bindningstider eller kortuppgifter krävs.
Prova nu
Köp en prenumeration
Utforska våra prenumerationslösningar och välj den som passar dina behov.
Välj din prenumeration